In vitro Cytotoxicity of the Antimicrobial Polypeptide Nisin on Blood Tumor Cells

DOI :
Tweet about this on TwitterShare on FacebookEmail this to someoneShare on Google+

Lorena Salazar; Elizabeth Rivas; Alequis Pavón; Guillermo Wiese; Camila Manzano; Paz Orellana; Ana Gutierrez-Moraga; Piedad Cortés-Cortés & Gino Corsini

Summary

Bacteriocins are antimicrobial peptides of ribosomal synthesis secreted by bacteria. Among these, nisin stands out, which has potential uses in antibiotic therapies, as a food bio preservative and probiotics. Nisin has also been reported to have cytotoxicity on neoplastic cell lines, but there is little information on its effect on blood tumor cells. Due to the potential use that nisin presents, it is relevant to determine the toxicity it presents on tumor cell lines of the blood type. For this, hemolytic activity tests were carried out on human erythrocytes and toxicity on human peripheral blood mononuclear cells, determining that nisin does not have a toxic effect on this type of normal human blood cells. Cytotoxicity tests were also carried out with tumor cell lines (K562 and U937), to determine dose, exposure time and selectivity in the toxic effect of nisin on human tumor cells. These tests show that nisin shows cytotoxic activity on K562 and U937 cell lines at 72 h of exposure, at a concentration of 40 μg / mL, which corresponds to 100 times the minimum inhibitory concentration (MIC) used for its action on bacteria. When comparing the effect of nisin on human peripheral blood mononuclear cells with lymphoid and myeloid tumor lines (K562 and U937 respectively), a selective effect of nisin on blood tumor cells is observed.

KEY WORDS: Nisin; Cytotoxicity; Bacteriocin; Blood tumor cells; K562 cell and U937 cells.

How to cite this article

SALAZAR, L.; RIVAS, E.; PAVÓN, A.; WIESE, G.; MANZA- NO, C.; ORELLANA, P.; GUTIERREZ-MORAGA, A.; COR- TÉS-CORTÉS, P. & CORSINI, G. In vitro cytotoxicity of the antimicrobial polypeptide nisin on blood tumor cells. Int. J. Morphol., 40(5):176-1283, 2022.